Theralink Technologies Inc.
Genomic assays do not provide actionable drug treatment information for a majority of cancer patients. Theralink Technologies specializes in Reverse Phase Protein Array (RPPA) Services for oncology treatment and drug discovery. Our patented proteomic technology, Theralink®, is the only commercial platform that measures the activation state of drug targets directly; enabling oncologists to individualize therapy and customizable for the biopharmaceutical industry for Protein Biomarkers/CDx development, patient stratification, and clinical trial applications.